Zobrazeno 1 - 10 of 71 pro vyhledávání: '"A M Zubiaga"'
1
Akademický článek
Sustained CHK2 activity, but not ATM activity, is critical to maintain a G1 arrest after DNA damage in untransformed cells
Autor: Iraia García-Santisteban, Alba Llopis, Lenno Krenning, Jon Vallejo-Rodríguez, Bram van den Broek, Ana M. Zubiaga, René H. Medema
Publikováno v: BMC Biology, Vol 19, Iss 1, Pp 1-13 (2021)
Abstract Background The G1 checkpoint is a critical regulator of genomic stability in untransformed cells, preventing cell cycle progression after DNA damage. DNA double-strand breaks (DSBs) recruit and activate ATM, a kinase which in turn activates
Externí odkaz: https://doaj.org/article/299072c998e041d3b68b95d3f854e145
Zobrazit plný text záznamu
7
Akademický článek
Does arterial hypertension influence the onset of Huntington's disease?
Autor: Leire Valcárcel-Ocete, Asier Fullaondo, Gorka Alkorta-Aranburu, María García-Barcina, Raymund A C Roos, Lena E Hjermind, Carsten Saft, Marina Frontali, Ralf Reilmann, Hugh Rickards, REGISTRY investigators of the European Huntington’s Disease Network (EHDN), Ana M Zubiaga, Ana Aguirre
Publikováno v: PLoS ONE, Vol 13, Iss 5, p e0197975 (2018)
Huntington's disease (HD) age of onset (AO) is mainly determined by the length of the CAG repeat expansion in the huntingtin gene. The remaining AO variability has been attributed to other little-known factors. A factor that has been associated with
Externí odkaz: https://doaj.org/article/40cbccc9864f42288a97f889c37be2d2
Zobrazit plný text záznamu
8
Targeting E2F Sensitizes Prostate Cancer Cells to Drug-Induced Replication Stress by Promoting Unscheduled CDK1 Activity
Autor: Mohaddase Hamidi, Ainhoa Eriz, Jone Mitxelena, Larraitz Fernandez-Ares, Igor Aurrekoetxea, Patricia Aspichueta, Ainhoa Iglesias-Ara, Ana M. Zubiaga
Publikováno v: Cancers; Volume 14; Issue 19; Pages: 4952
E2F1/E2F2 expression correlates with malignancy in prostate cancer (PCa), but its functional significance remains unresolved. To define the mechanisms governed by E2F in PCa, we analyzed the contribution of E2F target genes to the control of genome i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dda15439a427aeab07a57905a167b42
http://hdl.handle.net/10810/58133
Zobrazit plný text záznamu
9
Akademický článek
LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers.
Autor: Eguzkine Ochoa, Mikel Iriondo, Carmen Manzano, Asier Fullaondo, Irama Villar, Guillermo Ruiz-Irastorza, Ana M Zubiaga, Andone Estonba
Publikováno v: PLoS ONE, Vol 11, Iss 1, p e0146990 (2016)
The identification of the genetic risk factors that could discriminate non- thrombotic from thrombotic antiphospholipid antibodies (aPLA) carriers will improve prognosis of these patients. Several human studies have shown the presence of aPLAs associ
Externí odkaz: https://doaj.org/article/896de7fc4dd8410d948139cf0dfe9c75
Zobrazit plný text záznamu
10
Akademický článek
Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier Gene.
Autor: Leire Valcárcel-Ocete, Gorka Alkorta-Aranburu, Mikel Iriondo, Asier Fullaondo, María García-Barcina, José Manuel Fernández-García, Elena Lezcano-García, José María Losada-Domingo, Javier Ruiz-Ojeda, Amaia Álvarez de Arcaya, José María Pérez-Ramos, Raymund A C Roos, Jørgen E Nielsen, Carsten Saft, REGISTRY investigators of the European Huntington's Disease Network, Ana M Zubiaga, Ana Aguirre
Publikováno v: PLoS ONE, Vol 10, Iss 7, p e0131573 (2015)
Age of onset (AO) of Huntington disease (HD) is mainly determined by the length of the CAG repeat expansion (CAGexp) in exon 1 of the HTT gene. Additional genetic variation has been suggested to contribute to AO, although the mechanism by which it co
Externí odkaz: https://doaj.org/article/c7ff862050a64eca938de23d82fc92fb
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje